These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7769058)

  • 1. A randomized, assessor-blind, group-comparative efficacy study to compare the effects of Normegon and Metrodin in infertile female patients undergoing in-vitro fertilization.
    Devroey P; Tjandraprawira K; Mannaerts B; Coelingh Bennink H; Smitz J; Bonduelle M; De Brabanter A; Van Steirteghem AC
    Hum Reprod; 1995 Feb; 10(2):332-7. PubMed ID: 7769058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
    Frydman R; Howles CM; Truong F
    Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients.
    Jansen CA; van Os HC; Out HJ; Coelingh Bennink HJ
    Hum Reprod; 1998 Nov; 13(11):2995-9. PubMed ID: 9853844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study.
    Howles CM; Loumaye E; Giroud D; Luyet G
    Hum Reprod; 1994 Mar; 9(3):424-30. PubMed ID: 8006130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of gonadotrophins with differing LH/FSH ratios on the secretion of the various species of inhibin in women receiving IVF.
    Fawzy M; Harrison RF; Knight PG; Groome N; Anderson A; Robertson WR; Lambert A
    Hum Reprod; 2001 Jun; 16(6):1092-7. PubMed ID: 11387274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
    Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
    Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
    Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial.
    Hedon B; Out HJ; Hugues JN; Camier B; Cohen J; Lopes P; Zorn JR; van der Heijden B; Coelingh Bennink HJ
    Hum Reprod; 1995 Dec; 10(12):3102-6. PubMed ID: 8822422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective comparative study on IVF outcomes with either purified FSH or human menopausal gonadotrophin in downregulated normogonadotrophic women.
    Ismail AF; Hesham AI; Salah Z; Khaled M; Fouad N; Ashraf N; Hatem S; Hamdi B
    Gynecol Obstet Invest; 2002; 53(4):220-3. PubMed ID: 12186987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of follicle stimulating hormone versus human menopausal gonadotrophin in in-vitro fertilization.
    Daya S; Gunby J; Hughes EG; Collins JA; Sagle MA
    Hum Reprod; 1995 Jun; 10(6):1392-6. PubMed ID: 7593503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.
    Bergh C; Howles CM; Borg K; Hamberger L; Josefsson B; Nilsson L; Wikland M
    Hum Reprod; 1997 Oct; 12(10):2133-9. PubMed ID: 9402268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A randomized, controlled trial comparing follicle stimulating hormone (FSH) to human menopausal gonadotropin (hMG) in fertilization in vitro].
    Daya S; Gumby J; Hughes EG; Collins JA; Sagle MA
    Contracept Fertil Sex; 1995 Dec; 23(12):766-71. PubMed ID: 8556078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. On behalf of The Feronia and Apis study group.
    Schats R; Sutter PD; Bassil S; Kremer JA; Tournaye H; Donnez J
    Hum Reprod; 2000 Aug; 15(8):1691-7. PubMed ID: 10920087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A prospective, randomized controlled study comparing the effects of gonadotropin-releasing hormone agonist long and short protocols for in vitro fertilization].
    Ye H; Huang G; Pei L
    Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):222-5. PubMed ID: 11783366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization.
    Out HJ; Mannaerts BM; Driessen SG; Bennink HJ
    Hum Reprod; 1995 Oct; 10(10):2534-40. PubMed ID: 8567765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of highly purified FSH (metrodin-high purity) with pergonal for IVF superovulation.
    Bagratee JS; Lockwood G; López Bernal A; Barlow DH; Ledger WL
    J Assist Reprod Genet; 1998 Feb; 15(2):65-9. PubMed ID: 9513843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.